Wells Fargo & Co Reiterates Buy Rating for Amphastar Pharmaceuticals (AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “buy” rating reiterated by stock analysts at Wells Fargo & Co in a research report issued to clients and investors on Friday.

A number of other analysts have also recently weighed in on AMPH. BidaskClub cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 13th. Needham & Company LLC decreased their price target on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 10th. ValuEngine upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 17th. Finally, Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Amphastar Pharmaceuticals has a consensus rating of “Buy” and an average price target of $23.00.

NASDAQ AMPH opened at $21.59 on Friday. The company has a current ratio of 1.94, a quick ratio of 1.24 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $890.44 million, a P/E ratio of 56.82, a P/E/G ratio of 8.77 and a beta of 1.38. Amphastar Pharmaceuticals has a 12 month low of $14.40 and a 12 month high of $21.65.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, November 8th. The company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. The firm had revenue of $75.54 million for the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The company’s revenue was up 30.5% on a year-over-year basis. During the same period last year, the firm posted $0.07 EPS. On average, research analysts forecast that Amphastar Pharmaceuticals will post 0.1 EPS for the current fiscal year.

In related news, Director Richard K. Prins sold 10,000 shares of the stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $17.82, for a total transaction of $178,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Jason B. Shandell sold 16,095 shares of the stock in a transaction on Friday, November 9th. The stock was sold at an average price of $20.99, for a total transaction of $337,834.05. Following the sale, the general counsel now owns 204,805 shares of the company’s stock, valued at approximately $4,298,856.95. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,502 shares of company stock valued at $558,373. 31.50% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 5.9% in the 2nd quarter. BlackRock Inc. now owns 5,720,183 shares of the company’s stock worth $87,291,000 after acquiring an additional 318,360 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter worth $161,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter worth $128,000. Sei Investments Co. lifted its stake in shares of Amphastar Pharmaceuticals by 4.9% in the 2nd quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after acquiring an additional 3,193 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Amphastar Pharmaceuticals by 76.6% in the 2nd quarter. Renaissance Technologies LLC now owns 91,100 shares of the company’s stock worth $1,390,000 after acquiring an additional 39,500 shares during the period. Hedge funds and other institutional investors own 42.86% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Article: Buyback For Investors Defined

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply